Biotech Values

[mr_o]

Re: MON EPS growth

In my opinion this arbitrarily timed push for 20% EPS growth has to be the result of management incentives. There is no sound reason to incur 10 billion in debt over a 2 year span for buybacks. With 2 billion a year in FCF the company would have plenty of cash for moderately paced, self funded share repurchase plan.

In the presentation MON shows 2016 EPS estimates of $5.10 - 5.60, with an expected uplift of $.24 - $.27 EPS due to decreased share count. If the share count remained constant would 2016 EPS actually be $4.85 - $5.35?